Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-01-15

Clinical Trial Update: Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the efficacy and safety of NBI-1065845 in adults with major depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NBI-1065845

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED